aleniglipron vs regor GLP-1

NCT06703021 · Phase 2 · completed

The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT06867718 · Phase 2 · completed

The trial randomized 267 participants to four active-dose groups or placebo and masked both participants and investigators. Its primary endpoint was percent change in body weight at Week 36, but the registry does not report whether the comparison met its statistical objective, so the evidence is currently limited to a well-controlled study design with an unknown result.

NCT05762471 · Phase 1/2 · completed

The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.